ANTIBODIES SPECIFIC FOR FLT3 AND THEIR USES

The present invention provides antibodies that specifically bind to FLT3 (Fms- Like Tyrosine Kinase 3). The invention further provides bispecific antibodies that bind to FLT3 and another antigen (e.g., CD3). The invention further relates to antibody encoding nucleic acids, and methods of obtaining s...

Full description

Saved in:
Bibliographic Details
Main Authors DETTLING, Danielle Elizabeth, YEUNG, Yik Andy, SOMMER, Cesar Adolfo, KRISHNAMOORTHY, Veena, POULSEN, Kristian Todd
Format Patent
LanguageEnglish
French
Published 06.12.2018
Subjects
CHEMISTRY
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PEPTIDES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online AccessGet full text

Cover

More Information
Summary:The present invention provides antibodies that specifically bind to FLT3 (Fms- Like Tyrosine Kinase 3). The invention further provides bispecific antibodies that bind to FLT3 and another antigen (e.g., CD3). The invention further relates to antibody encoding nucleic acids, and methods of obtaining such antibodies (monospecific and bispecific). The invention further relates to therapeutic methods for use of these antibodies for the treatment of FLT3-mediated pathologies, including cancer such as Acute Myeloid Leukemia (AML). La présente invention concerne des anticorps qui se lient spécifiquement à FLT3 (Tyrosine kinase 3 de type Fms). L'invention concerne en outre des anticorps bispécifiques qui se lient à FLT3 et à un autre antigène (par exemple, CD3). L'invention concerne également des acides nucléiques codant pour des anticorps, et des procédés permettant d'obtenir de tels anticorps (monospécifiques et bispécifiques). L'invention concerne en outre des méthodes thérapeutiques d'utilisation de ces anticorps pour le traitement de pathologies médiées par FLT3, notamment un cancer tel que la leucémie myéloïde aiguë (AML).
Bibliography:Application Number: WO2018IB53908